Latest Articles and Analysis

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Analysis of hepatitis B vaccine efficacy and revaccination protocols for people living with HIV.

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.